Status:
RECRUITING
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Alopecia Areata
Janus Kinase Inhibitors
Eligibility:
All Genders
2-80 years
Brief Summary
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still m...
Eligibility Criteria
Inclusion
- Patients with alopecia areata between 2 to 18 years old
- Patients diagnosed with alopecia areata according to AA guideline
- AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months
Exclusion
- Patients had previously received hair implants
- Other alopecia
- Other diseases may induce alopecia including psoriasis, lichen planus, et al.
- Unable to estimate SALT score at baseline or at follow-up
- Patients are participating in other clinical trials
Key Trial Info
Start Date :
July 29 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06573593
Start Date
July 29 2024
End Date
December 31 2026
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China, 310009